Compare Nasdaq Inc (NDAQ) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Nasdaq Inc trades at $91.96 (market cap $52.25B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Nasdaq Inc is far larger — about 6.9× Spyre Therapeutics Inc. Common Stock's market cap, and Nasdaq Inc pays a 1.24% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq Inc for 126 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| NDAQ | SYRE | |
|---|---|---|
Market Cap | $52.25B | $7.52B |
Volume | 2,420,834 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $100.98 | $108.92 |
52-Week Low | $76.85 | $22.18 |
Typical Hold Time | 126 Days | 0 Days |
Enterprise Value | $58.71B | $6.52B |
Dividend Yield | 1.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $91.96, down 2.47% on the day, with a bullish technical outlook supported by moving averages. The company shows strong fundamentals with 2025 revenue of $8.26B and net income of $1.79B, achieving a 21.64% profit margin. Recent earnings beats and analyst consensus of $110.43 price target reflect confidence in growth driven by financial technology and AI initiatives.
NDAQ presents a compelling investment case with solid profitability and strategic positioning in market infrastructure. Key risks include market volatility sensitivity and debt levels, but strong cash flow and institutional support provide stability. The stock offers upside potential aligned with analyst targets, supported by recurring revenue growth and technology adoption.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
